TrippBio is a new biotechnology company dedicated to the discovery of treatments for infectious diseases with a specialization in emerging respiratory viruses. TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to prevent and treat rogue viruses, like SARS-CoV-2, the virus that causes COVID-19.
One such drug is currently in an advanced phase of testing, TD213. This drug is showing great potential and if proven successful, could be a unique mechanism of action to help millions.
And this is where you come in.
This investment opportunity is an amazing chance for you to get in on the ground floor
of this dynamic pivot in the treatment and prevention of viruses.
It's why we say WOW.
THE TRIPP IN TRIPPBIO
He has continued this important exploration as Georgia Research Alliance Chair and professor in vaccine and therapeutic development at the University of Georgia, leading to the development of a drug with incredible potential in the treatment of COVID-19 and other viral infections.
The world simply cannot afford to wait for new drugs to be developed. That's why TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to prevent and treat rogue viruses, starting with SARS-CoV-2, the virus that causes COVID-19.
THE TEAM
Billy Meadow
CHAIRMAN
Philip J. Young
President & CEO
Dr. Ralph A. Tripp
Chief Science Officer
Our Story
Check out our story in this compelling video about the journey of Dr. Tripp and his team's road to the launch of TrippBio.
